Abbreviations: BP, blood pressure; CTG, cardiotocography; PlGF, placental growth factor. 1.4.4 Offer placental growth factor (PlGF)-based testing to help rule out pre- eclampsia in women presenting with suspected pre-eclampsia (for example, with gestational hypertension) between 20 weeks and 36 weeks and 6 days of pregnancy. (See the NICE diagnostics guidance on PlGF-based testing to help diagnose suspected preterm pre-eclampsia.) 1.4.5 Consider labetalol to treat gestational hypertension. Consider for women in whom labetalol is not suitable, and methyldopa if labetalol or nifedipine[3] are not suitable. Base the choice on side-effect profiles, risk (including fetal effects) and the woman's preferences. 1.4.6 Do not offer bed rest in hospital as a treatment for gestational To find out why the committee made the 2019 recommendations on the monitoring and treatment of gestational hypertension and how they might affect practice, see rationale and impact. Timing of birth 1.4.7 Do not offer planned early birth before 37 weeks to women with gestational hypertension whose blood pressure is lower than 160/ 110 mmHg, unless there are other medical indications. [2010, amended 1.4.8 For women with gestational hypertension whose blood pressure is lower than 160/110 mmHg after 37 weeks, timing of birth, and maternal and fetal indications for birth should be agreed between the woman and the senior obstetrician. [2010, amended 2019] 1.4.9 If planned early birth is necessary (see recommendation 1.5.7), offer a course of antenatal corticosteroids and magnesium sulfate if indicated, in line with the NICE guideline on preterm labour and birth. [2010, amended Postnatal investigation, monitoring and treatment 1.4.10 In women with gestational hypertension who have given birth, measure blood pressure: daily for the first 2 days after birth at least once between day 3 and day 5 after birth as clinically indicated if antihypertensive treatment is changed after birth. 